Chen Hua-Ping, Han Xiao, Sun Hui-Ping, Xie Tao, Fan Xiao-Liang
Orthopedics, Affiliated Hangzhou First People's Hospital , School Of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China.
Heliyon. 2024 Feb 29;10(5):e27191. doi: 10.1016/j.heliyon.2024.e27191. eCollection 2024 Mar 15.
This study aims to explore the clinical value of P4HA2 (prolyl 4-hydroxylase subunit alpha 2) in Osteosarcoma (OSC), and assess its potential to provide directions and clues for the practice of precision nursing.
The GSE73166 and GSE16088 datasets were used to explore the P4HA2 expression in OSC. We then used the clinical data of patients obtaining from TARGET database to assess the prognostic value of P4HA2 in OSC. We also evaluated the predictive value of prognostic model based on P4HA2-related genes. Further, GSEA analysis was performed to explore related pathways.
The P4HA2 mRNA expression was higher in OSC than that in normal tissues and other bone cancer samples. Survival analysis found that P4HA2 high expression caused poor overall survival (OS) of patients with OSC and P4HA2 presented a favorable performance for predicting OS. Specifically, P4HA2 high expression statistically influenced the OS of patients with age≥15 years old and those with or without metastasis. Cox regression analysis indicated the independent prognostic value of P4HA2 in OSC, and nomogram analysis revealed its significant contribution to the survival probability of patients. We further established a prognostic model based on P4HA2-related genes, finding that prognostic model had a good prediction ability on OS. These results supported the clinical significance of P4HA2 in OSC. GSEA analysis suggested that P4HA2 was significantly related to the MAPK signaling pathway. In addition, P4HA2-associated natural killer cell-mediated cytotoxicity and T cell receptor signaling pathway were also predicted.
This study revealed that P4HA2 can serve as an important prognostic biomarker for OSC patients, and it may become a promising therapeutic target in OSC treatment.
本研究旨在探讨脯氨酰4-羟化酶α2亚基（P4HA2）在骨肉瘤（OSC）中的临床价值，并评估其为精准护理实践提供方向和线索的潜力。
使用GSE73166和GSE16088数据集探究OSC中P4HA2的表达情况。然后利用从TARGET数据库获取的患者临床数据评估P4HA2在OSC中的预后价值。我们还评估了基于P4HA2相关基因的预后模型的预测价值。此外，进行基因集富集分析（GSEA）以探索相关通路。
OSC中P4HA2 mRNA表达高于正常组织和其他骨癌样本。生存分析发现，P4HA2高表达导致OSC患者总体生存期（OS）较差，且P4HA2在预测OS方面表现良好。具体而言，P4HA2高表达在统计学上影响年龄≥15岁以及有无转移患者的OS。Cox回归分析表明P4HA2在OSC中具有独立预后价值，列线图分析显示其对患者生存概率有显著贡献。我们进一步建立了基于P4HA2相关基因的预后模型，发现该预后模型对OS具有良好的预测能力。这些结果支持了P4HA2在OSC中的临床意义。GSEA分析表明P4HA2与丝裂原活化蛋白激酶（MAPK）信号通路显著相关。此外，还预测了与P4HA2相关的自然杀伤细胞介导的细胞毒性和T细胞受体信号通路。
本研究表明，P4HA2可作为OSC患者重要的预后生物标志物，且可能成为OSC治疗中有前景的治疗靶点。
